Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation by Poonkuzhali, B. et al.
Bone Marrow Transplantation, (1999) 24, 5–11
Ó 1999 Stockton Press All rights reserved 0268–3369/99 $12.00
http://www.stockton-press.co.uk/bmt
Pharmacokinetics of oral busulphan in children with beta
thalassaemia major undergoing allogeneic bone marrow
transplantation
B Poonkuzhali1, A Srivastava1, MH Quernin2, D Dennison1, EJ Aigrain2, AS Kanagasabapathy3,
R Krishnamoorthy4 and M Chandy1
Departments of 1Hematology and 3Clinical Biochemistry, Christian Medical College and Hospital, Vellore, India; Department of
2Pharmacology and 4INSERM U 458, Hoˆpital Robert Debre, Paris, France
Summary:
The pharmacokinetics of busulphan were studied in 23
thalassaemic children undergoing BMT. Patients
received busulphan at a dose of either 16 mg/kg with
cyclophosphamide and ATG (Group A) or 600 mg/m2
(with cyclophosphamide alone) (Group B) in 16 divided
doses every 6 h over 4 days. Busulphan levels were ana-
lyzed by a modified GC-MS method. The dose of
busulphan/kg for patients in group B was 64% (range
56–71%) higher than that for patients in group A. The
mean AUC, Css, Cmax and MRV were significantly
higher in group B as compared with group A for both
doses 1 and 13. There was no significant difference in
Vd/F, T1/2 and Kel between the two groups. A signifi-
cant decrease in AUC and Css was found between 1st
and 13th doses in group B, but not in group A. The Cl/F
values in group A were significantly higher than those
in group B after dose 1, but not after dose 13. No
increase in toxicity due to the higher dose of busulphan
was noted. We conclude that busulphan at 600 mg/m2
results in much higher systemic exposure to the drug as
compared to 16 mg/kg, without increase in toxicity in
children with beta thalassaemia major.
Keywords: busulphan; pharmacokinetics; bone marrow
transplantation; thalassaemia
Busulphan is widely used in conditioning regimens for
patients undergoing bone marrow transplantation (BMT).1–6
It is most commonly used at 16 mg/kg (total dose) over 4
days. Lucarelli et al6 have used a total of 14–16 mg/kg of
busulphan in thalassaemic children undergoing BMT.
Rejection of the graft is a major cause of failure among
them and occurs in up to 32% of class III patients.6 Recent
studies have shown that children may need a higher dose
(600 mg/m2) to achieve the same systemic exposure to the
drug as adults.7 It is possible that this may help reduce the
high incidence of graft rejection in these patients. There
has been concern about the toxicities of busulphan at such
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a high dose. Pharmacokinetic data of busulphan in adults
have shown a significant correlation between systemic
exposure, particularly the area under the concentration vs
time curve (AUC) and the incidence of veno-occlusive dis-
ease (VOD) of the liver.8 However, many studies have
demonstrated that children undergoing BMT for both
malignant and genetic disorders7,9–11 tolerate this dose well.
There are limited data on the pharmacokinetics of busul-
phan at 16 mg/kg in children with beta thalassaemia major,
most of whom have varying degrees of chronic liver dis-
ease.12,13 There are no data regarding the pharmacokinetics
of busulphan at 600 mg/m2 in this group of patients. In this
report, we describe the comparative pharmacokinetics of
busulphan at these two dosages, 16 mg/kg and 600 mg/m2,
in conditioning therapy for BMT for heavily transfused
thalassaemic children.
Patients and methods
Patients and treatment
Twenty-three consecutive children with thalassaemia
major, who underwent allogeneic BMT from HLA-matched
sibling donors, were included in this study. Patients were
randomized to receive busulphan (Myeleran; Glaxo Well-
come, Madrid, Spain) 4 mg/kg p.o. in divided doses every
6 h daily for 4 days (total dose 16 mg/kg) on days - 9 to
- 6 and cyclophosphamide 50 mg/kg once daily i.v. on days
- 5 to - 2 with ATG 30 mg/kg (Lymphoglobuline, Pasteur
Meriuex, Paris, France) on days - 4 to - 2 (group A) or
busulphan 600 mg/m2 (total dose) p.o. in divided doses
every 6 h daily for 4 days on days - 9 to - 6 and cyclophos-
phamide 50 mg/kg once daily i.v. on days - 5 to - 2 (group
B) before BMT. All patients received 7.5 mg/kg p.o. of
phenytoin in divided doses as prophylaxis against seizures,
starting 1 day before and stopping 1 day after busulphan
treatment. Eleven patients were in group A and 12 in group
B. Informed consent was obtained from the parents of all
patients. The study was approved by the institutional
review board.
Sample collection
The first dose of busulphan was given at 6 am to all
patients. All doses were given to patients on an empty sto-
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Table 1 Details of patients and individual dosage of busulphan
No. Age Weight (kg) BSA (m2) Risk categorya Bu dose (mg/kg) % Excess
Group A: Busulphan 16 mg/kg with cyclophosphamide 200 mg/kg and ATG
1 6 19 0.75 III 16
2 8.5 21 0.84 III 16
3 11 25 1.0 II 16
4 11 31 1.1 III 16
5 7.5 20 0.84 III 16
6 9 22 0.84 III 16
7 5.5 15 0.67 II 16
8 5 19 0.73 III 16
9 8 20 0.67 III 16
10 4 15 0.67 II 16
11 13 35 1.24 III 16
Mean 8.05 22 0.85 16
Group B: Busulphan 600 mg/m2 with cyclophosphamide 200 mg/kg
1 2.5 13 0.54 II 20 64
2 7 21 0.85 III 32 66
3 4 17 0.65 II 24 71
4 2.5 13.5 0.57 II 21 64
5 10 23 0.9 III 34 68
6 5 20.5 0.65 II 24 68
7 8 20.5 0.83 II 31 68
8 6 19 0.8 III 30 62
9 6 15.5 0.66 III 25 56
10 12 22 0.87 III 33 56
11 4 13.5 0.65 III 24 67
12 11 25.5 0.95 III 36 62
Mean 6.5 19 0.74 27.8 64
aAs per Lucarelli et al.29
mach. Blood samples (3–5 ml) were taken from a central
venous catheter into glass tubes containing 150 IU heparin.
They were collected immediately before starting the drug
and at 0.5, 1, 1.5, 2, 4 and 6 h after the first, second and
13th doses. Samples were immediately refrigerated and
centrifuged within 1.5–3 h of collection and stored at
- 80° C until analysis. Busulphan in plasma samples was
found to be stable for up to 2 years at - 80° C. Samples
analysed after 6 months, 1 year and 2 years of storage after
collection showed good correlation (r = 0.89, P , 0.001)
(unpublished data).
Busulphan assay
Samples were analysed by a modified GC-MS method14 as
previously reported. Briefly, busulphan in plasma was
mixed with 100 ml internal standard-d8-busulphan (1,4-but-
anediol-1,1,2,2,3,3,4,4,-d8) and extracted with ethyl acetate
for 10 min. The organic layer was separated and allowed
to evaporate at 60° C under nitrogen gas. The residue was
subjected to derivatization by adding 1 m 2,3,5,6, tetrafluo-
rothiophenol and 1 m sodium hydroxide and heated at 70 ° C
for 2 h. It was then mixed with ethyl acetate and 1 m
sodium hydroxide, for extraction of the derivatized com-
pound. The organic phase was dried under nitrogen gas and
the residue dissolved in 100 ml of ethyl acetate. An aliquot
of 1 ml was injected into the GC-MS system. The gas chro-
matographic system was a Hewlett Packard (California,
USA) model 5890 equipped with a CP sil5CB WCOT fused
silica capillary column (25 m · 0.25 mm ID) with a film
thickness of 0.12 mm (Chrompack, Middleburg, The
Netherlands). Helium was used as the carrier gas at a flow
rate of 1.9 ml/min. The oven temperature was initially kept
at 60° C for 1 min then increased with a first gradient of
35° C/min to 170° C and maintained for 3 min, a second
gradient of 4° C/min to 200 ° C and a third 35 ° C/min to
250° C. The injector was in the splitless mode and heated
at 250 ° C. The autosampler tray was refrigerated at 4 ° C.
Detection was performed with a Hewlett Packard mass
spectrometer model 5971A equipped with an electron
impact source (tuned to m/z 237 and 245 for derivatized
busulphan and derivatized-d8 busulphan, respectively). For
the mass spectral identification of busulphan and busul-
phan-d8, a chemical ionization (CI) source was employed
with methane as the reagent gas. The two sources were
heated at 175 ° C.
Pharmacokinetic analysis
Pharmacokinetic analysis was done using the ‘TOPFIT’
program.15 Parameters including elimination half-life
(T1/2), elimination rate constant (Kel), AUC were esti-
mated directly from the data using non-compartmental
analysis. T1/2 was determined from the linear portions of
the log plasma AUC curves. All the other parameters
were derived.
The mean concentration at steady state (Css) was calcu-
lated from the following formulae: expected Css = AUC0-
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Table 2A Intergroup comparison of busulphan pharmacokinetic parameters of doses 1 and 13
Parameter Dose 1 Dose 13
(units)
Group A, 16 mg/kg Group B, 600 mg/m2 P value Group A, 16 mg/kg Group B, 600 mg/m2 P value
(mean – s.d.) (mean – s.d.) (mean – s.d.) (mean – s.d.)
Age (years) 8 – 2.8 6.1 – 3 NS
Number 11 12 NS
Dose (mg/kg) 16 27.8 – 5.4 0.0092
Cmax 949 – 278 1579 – 400 0.0015 1147 – 355 1645 – 316 NS
Tmax 1.4 – 0.6 1.85 – 1.58 NS 1.5 – 1.0 1.1 – 0.57 0.006
AUC (ng*h/ml) 3167 – 878 6287 – 1194 0.0002 3485 – 1210 5083 – 1039
(range) (1971–4590) (4888–8659) (2244–6322) (3859–6717)
Cl/f (ml/min/kg) 5.66 – 1.688 4.15 – 1.06 0.037 5.24 – 1.5 5.11 – 1.04 NS
(range) (3.6–8.5) (2.66–6.03) (2.67–7.41) (3.4–6.58)
Vd/f (l/kg) 0.94 – 0.3 0.79 – 0.2 NS 0.91 – 0.3 1.05 – 0.64 NS
T1/2 (h) 1.92 – 0.42 2.17 – 0.55 NS 2.14 – 0.9 2.29 – 1.1 NS
Kel 0.38 – 0.077 0.34 – 0.12 0.0815 0.37 – 0.1 0.35 – 0.12 NS
Css (ng/ml) 528 – 146 1048 – 199 0.0025 581 – 202 847 – 173 NS
MRV (ng/ml) 202 – 78 420 – 145 0.0012 *** *** ***
AUC = area under the concentration curve (ng*h/ml); Cmax = maximum concentration (ng/ml); Tmax = time for maximum concentration (h); T1/2 =
elimination half-life (h); Kel = elimination rate constant; Cl/F = clearance (ml/min/kg); Vd/F = volume of distribution (l/kg); Css = steady-state
concentration (ng/ml); MRV = mean residual value (ng/ml); NS = not significant.
Table 2B Intra-group comparison of busulphan pharmacokinetic
parameters of doses 1 and 13
1st dose 13th dose P value
(mean – s.d.) (mean – s.d.)
Group A (16 mg/kg)
Cmax 949 – 278 1147 – 355 NS
Tmax 1.4 – 0.6 1.1 – 0.57 NS
AUC (ng.h/ml) 3167 – 878 3485 – 1210 NS
Cl/F (ml/min/kg) 5.66 – 1.688 5.24 – 1.25 NS
Vd/F (l/kg) 0.94 – 0.3 0.91 – 0.3 NS
T1/2 (h) 1.92 – 0.42 2.14 – 0.9 NS
Kel (per h) 0.38 – 0.077 0.37 – 0.1 NS
Css (ng/ml) 528 – 146 581 – 202 NS
Group B (600 mg/m2)
Cmax 1579 – 400 1645 – 316 NS
Tmax 1.85 – 1.58 1.1 – 0.57 NS
AUC (ng.h/ml) 6287 – 1194 5083 – 1039 0.03
Cl/F (ml/min/kg) 4.15 – 1.06 5.11 – 1.04 0.06
Vd/F (l/kg) 0.79 – 0.2 1.05 – 0.64 NS
T1/2 (h) 2.17 – 0.55 2.29 – 1.1 NS
Kel (per h) 0.34 – 0.12 0.35 – 0.12 NS
Css (ng/ml) 1048 – 199 847 – 173 0.05
Abbreviations as in Table 2A.
a of 1st dose/dosing interval, ie 6 h; observed
Css = AUC0–6 h of the 13th dose/dosing interval. Clear-
ance (Cl/F) was calculated as the ratio of dose to AUC.
Vd/F (in L/kg) was calculated as the ratio of Cl/F to Kel.
Mean residual value (MRV) was calculated as the mean of
all trough levels from dose 2 to dose 16. Maximum concen-
tration (Cmax) was the peak value of busulphan after the
first and 13th doses.
Analysis of outcome
Regimen-related toxicities were documented according to
the grading system of Bearman et al.16 VOD was defined
by the presence of hepatomegaly, ascites and hyperbilirubi-
nemia as previously described by Jones et al17 and McDon-
ald et al.18 Idiopathic interstitial pneumonia was diagnosed
on the basis of clinical and radiological features after
infectious agents were excluded.
Statistical analysis
Mean and standard deviations were calculated for all phar-
macokinetic parameters. These parameters were compared
by the Mann–Whitney U test and Wilcoxon rank sum test.
The difference in busulphan AUC and Css values between
those who developed VOD and those who did not was ana-
lyzed by the two-tailed Student’s t-test. The differences in
the incidence of VOD in the two groups were analyzed by
Fisher’s exact probability test.
Results
Patients and protocols
The patients’ age, sex, body weight, body surface area
(BSA), status at BMT, busulphan dose and the excess dose
received by children in group B are given in Table 1. The
mean age, weight, BSA and pre-BMT bilirubin, transamin-
ases and serum ferritin in both these groups were compara-
ble. A total of 39 curves from 23 patients was available
for analysis, because sample collection was stopped in two
patients after the 1st dose and started in four patients after
the 1st dose. In one patient, after the 1st dose, the busulphan
plasma concentration continued to increase until 6 h, and
so it was not possible to calculate T1/2 and other kinetic
parameters. Patients receiving the 600 mg/m2 dose of bus-
ulphan, received a mean of 64% (range 56–71%) higher
dose by weight as compared to the 16 mg group.
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Table 3 Comparison of busulphan kinetic parameters in patients with and without VOD by Jones’s criteria
Parameter VOD (Jones)17 No VOD P value
1st dose 13th dose 1st dose 13th dose 1st dose 13th dose
Cmaxa (mean – s.d.) 960 – 373 1442 – 544 1009 – 258 1066 – 196 0.84 0.35
AUCa (mean – s.d.) 3242 – 316 4449 – 2050 3736 – 1128 3268 – 619 0.16 0.42
Cssa (mean – s.d.) 540 – 52 742 – 342 623 – 188 545 – 103 0.16 0.42
aAll values have been corrected to busulphan dose in mg/kg.
Table 4 Comparison of pharmacokinetic parameters of busulphan at 600 mg/h2 with previous studies
Parameters Vassal7 Yeager11 Shaw10a Present study
No. of patients 27 7 12 12
Dose 37.5 mg/m2/dose 40 mg/m2/dose 150 mg/m2/day 37.5 mg/m2/dose
Age (years) 2–14 1.1–5.7 5.5 2.5–12
Cmax (ng/ml) 1258 4953 – 1114 1579
AUC (ng*h/ml) 6404 – 2378 4530 – 1918 29388 – 8295 6287 – 1194
(range) (3566–13129) (3280–8528) – (4888–8659)
Cl/F (ml/min/kg) 4.5 – 1.4 — 3.44 – 1.13 4.15 – 1
Half life (h) 2.94 — 2.48 – 0.5 2.17
Vd/F (1/kg) 1.04 – 0.38 — 0.7 – 0.10 0.79 – 0.2
aBusulphan administered as a single daily dose. In all the other studies, busulphan was administered in four divided doses every day.
Pharmacokinetic analysis
Pharmacokinetic parameters calculated by non-compart-
mental analysis are given in Tables 2A and B.
Intergroup variation: AUC, Cmax, Css and MRV of doses
1 and 13 were significantly higher in group B than in group
A. Cl/F values, corrected to body weight, were significantly
higher in group A than in group B after the 1st dose
(P = 0.037) but not after the 13th dose. There was no sig-
nificant difference in other parameters such as T1/2, Tmax,
Kel and Vd/F between the two groups (Table 2A).
Intra- and inter-individual variations: Within group B,
there was a significant decrease in AUC (P = 0.037) and a
trend for significant increase in Cl/F values (P = 0.06)
between dose 1 and 13. All other parameters showed no
significant difference between doses. Expected and
observed Css were not significantly different in group A but
there was a significant decrease in observed Css of group B
(P = 0.05) (Table 2B). Within the same group, there was a
two- to 12-fold inter-individual variation in parameters
such as Cl/F, Cmax, T1/2, AUC and MRV. Some patients
who received 16 mg/kg busulphan achieved a Cmax similar
to those seen in patients receiving the higher dose of
600 mg/m2.
Busulphan toxicity
There was no correlation between busulphan AUC, Cmax
and Css and the incidence of hepatic toxicity. Regimen-
related hepatic toxicity as graded by the system of Bearman
et al16 was as follows: group A: 8/11 (grade I – one, grade
II – six and grade III – one); group B: 7/12 (grade II –
seven). Patients who developed VOD did not have a higher
AUC as compared to those who did not have VOD (Table
3). In fact, the mean of first dose AUC was higher in those
who did not develop VOD. Only three children, all of
whom were in group A, had VOD according to Jones’s
criteria.17 By McDonald’s criteria,18 9/11 patients in group
A and 7/12 patients in group B had VOD. However, these
differences were not statistically significant. None of these
patients had seizures or interstitial pneumonia.
Discussion
This is the first randomized prospective study comparing
the pharmacokinetics of two different dosages of busulphan
in a uniform group of patients – children with thalassaemia
major. Although the evaluation of busulphan kinetics
started with the development of a GC-MS method for its
assay by Ehrsson et al19 in 1983, most clinical studies have
involved heterogeneous patient populations. In 1997, Paw-
lowska et al13 reported the kinetics of busulphan in the dose
range of 14–16 mg/kg and correlated it with the outcome
of BMT in 64 children and young adults with thalassaemia
major. However, the kinetics of a higher dose of 600 mg/m2
has not been evaluated in a homogeneous population.
Earlier studies7,11 have reported that a higher dose of bus-
ulphan, based on body surface area, would be required in
young children to produce systemic exposure similar to
adults and overcome age-dependent variation in kinetics.
This would provide a greater antitumour, myeloablative and
immunosuppressive effect20 than the usual 16 mg/kg dose.
Our data show that by administering busulphan at
600 mg/m2, patients received a 64% higher dose of busul-
Busulphan pharmacokinetics in thalassaemia
B Poonkuzhali et al
9phan than would have been the case had they received
16 mg/kg. This resulted in a much higher AUC in these
patients (P , 0.0002) (Figure 1). In fact, children treated
with the 600 mg/m2 dose in our study achieved AUCs simi-
lar to those of adults treated with 16 mg/kg in another
study21 (6287 – 1194 vs 6520 – 1845, P = 0.71). Other bus-
ulphan kinetic parameters such as Cmax, Cl/F, Vd/F and
T1/2 in children receiving the higher dose of busulphan in
our study are similar to previous reports (Table 4).7,10,11
Shaw et al10 did not find any significant difference in busul-
phan Cl/F values between those given 16 mg/kg and
600 mg/m2 in patients with malignant disorders receiving
busulphan as a single daily dose. This difference may be
attributed to the frequency of administration of busulphan.
By a single daily dose, steady state can be attained at a
faster rate and the steady-state trough plasma levels are
lower than when the drug is administered once in 6 h.10
This results in a shorter T1/2 and Cl/F even though the
AUC and Cmax values are five and three times higher,
respectively, than we observed. Similar to the report of
Shaw et al,10 we did not observe any significant difference
in the other pharmacokinetic parameters including Vd/F,
Kel, T1/2 and Tmax between the two groups, suggesting
that these parameters are not dose dependent.
There are conflicting reports about the intraindividual
variability in busulphan kinetics. Among patients receiving
16 mg/kg, there was a correlation between the expected
(calculated from the extrapolated 1st dose AUC) and
observed Css and AUC values (r = 0.6, P , 0.01), showing
that there is no accumulation of the drug, and busulphan
pharmacokinetics are linear in children with thalassaemia
undergoing BMT. This observation was similar to recent
studies in thalassaemic children12 and in children with
malignant disorders,22 in which kinetic analysis of first and
last dose using AUC, Cmax and Cmin were comparable
and showed no sign of accumulation or decline in busul-
phan plasma levels over time. Therefore, the AUC after the
first dose can be a good predictor of AUC at steady state
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Figure 1 Representative busulphan concentration-time curve for a child receiving 16 mg/kg and another receiving 600 mg/m2. The points between
doses 1 and 13 are the trough levels before each dose.
for this dose of busulphan. Hassan et al21 have found a 25–
50% lower trough concentration after the last dose than the
1st dose in infants and older children receiving 16 mg/kg.
Other studies have also reported insignificant increases and
decreases11,23 but there was no significant change in trough
concentrations in our study.
Previous studies in children treated with 600 mg/m2 bus-
ulphan did not show any significant intra-individual varia-
bility.7,10,11 Our data show that in children receiving
600 mg/m2, there is a significant decrease in AUC, Css, and
a significant increase in Cl/F of the 13th dose when com-
pared to the 1st dose. Therefore, in these patients, 1st dose
AUC may not be predictive of AUC at steady state. In stud-
ies on children with malignant disorders, Vassal et al7 and
Yeager et al11 have shown no alteration between 1st dose
and steady-state AUCs, when busulphan dose was based
on body surface area. It is difficult to explain this difference
between these studies. The present study included only chil-
dren with beta thalassaemia major. Influence of underlying
disease process on busulphan kinetics has been reported
earlier.9,24
Wide inter-individual variations have been reported on
the same dose of busulphan in various pharmacokinetic
parameters. We observed two- to 12-fold inter-individual
variations. Other studies in children10,12,24 have shown a
six- to 20-fold variation in Cl/F, Vd/F and AUC. This sug-
gests that individual variables such as busulphan bio-avail-
ability and metabolism affect plasma levels of the drug.
The rate of metabolism of the absorbed drug could also
vary, resulting in widely varying systemic exposure. Hassan
et al,21 in their pharmacokinetic studies in children with
malignant disorders, suggested that the wide inter-individ-
ual variation in busulphan kinetics may be attributed to the
differences in the levels of glutathione or GST in the liver.
However, this has not yet been documented in any study.
If clear correlation can be established between busulphan
pharmacokinetics and outcome of BMT, then these data
emphasize the need for individual dose adjustment for
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vidual variability and systemic exposure to busulphan.
Hepatic enzyme inducers such as phenytoin or phenobar-
bital, given as prophylaxis against seizures to patients
receiving busulphan therapy for BMT have been shown to
influence its kinetics.25,26 Hassan et al21 reported a decrease
in plasma busulphan levels over time in about 40% of
adults and children and postulated that busulphan may
induce its own metabolism. Subsequently, they attributed
this decrease to the concomitant administration of pheny-
toin.26 In this study comparing busulphan at 16 mg/kg and
600 mg/m2, both groups received phenytoin but only chil-
dren receiving the higher dose of busulphan showed
decreased AUC, Css and enhanced Cl/F of the drug at
steady state. This could suggest that busulphan may induce
its own metabolism at higher dosage by putatively switch-
ing on GST enzymes. However, the role of phenytoin in the
occurrence of this dose-dependent alteration of busulphan
pharmacokinetics between the 1st and 13th doses cannot
be totally excluded.
Previous studies in children with malignant disorders9,27
have shown that by giving a dose of 600 mg/m2, there was
an increased incidence of hepatic VOD.28 In this study, no
significant difference in the incidence of VOD between
children receiving 16 mg/kg and 600 mg/m2 was noted.
There was no correlation between the busulphan AUC, Css
and Cmax with the occurrence of VOD. In fact, the 1st
dose AUC values are higher in those who did not develop
VOD. However, since the numbers of patients evaluated in
each group in our study are small, this observation needs
to be carefully interpreted. Our results are similar to a pre-
vious study in thalassaemic children receiving standard
16 mg/kg dose of busulphan where there was no association
between AUC and the incidence of VOD and other tox-
icities associated with busulphan conditioning.13 None of
these patients developed seizures or interstitial pneumonia.
We conclude that much higher systemic exposure to bus-
ulphan is achieved by children with thalassaemia major
who receive 600 mg/m2 of the drug compared with those
receiving 16 mg/kg as shown by the high Cmax, AUC,
MRV and Css. It is well tolerated by these patients, as evi-
denced by no increase in regimen-related toxicity. The two-
to 12-fold inter-individual variations in pharmacokinetics
and the differences in clearance values among the two
groups may be due to variations in busulphan bio-avail-
ability or the levels of GST in the liver. This is presently
being evaluated in these patients. Whether this increase in
systemic exposure to busulphan in children receiving the
600 mg/m2 dose will result in reduced rejection and relapse
of thalassaemia will be apparent when this ongoing study
is completed and adequate follow-up data are available on
larger numbers of patients. Therapeutic drug monitoring
and individual dose adjustment of busulphan might reduce
this inter-individual variation and improve transplant
outcome.
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